Inactive

This is a notice of intent, not a request for a quotation. A solicitation document will not be issued, and quotations will not be requested. The Translational Immunopsychiatry Unit (TIU) of the Nation... This is a notice of intent, not a request for a quotation. A solicitation document will not be issued, and quotations will not be requested. The Translational Immunopsychiatry Unit (TIU) of the National Institute of Mental Health (NIMH) intends to award a purchase of 90/90 Human ORFeome V 3 (Gateway Entry Vectors) - Complete Collection to: Arizona State University Biodesign Institute KE Finance Services and Recharge Centers DNASU Plasmid Repository PO Box 878008 Tempe, AZ 85287-8008 Market Research has provided that only DNASU can provide Human ORFeome 90/90 V3 Complete Collection, to the exact quality and quantity needed. TIU must be able to validate candidate autoantigens identified in autoantibody/autoantigen screens. Because this is discovery research, we do not know a priori which candidate autoantigens we will be identified for downstream validation studies. Autoantibodies may target any isoform of any protein and subsequent validation studies will include a diverse array of immunoaffinity assays. Therefore, TIU needs a comprehensive collection of human genes suitable for subcloning into diverse expression vectors. As such, we are requesting to purchase a cost-effective renewable source of most human genes that is suitable for cloning into expression vectors of our choice. The role of autoantibodies as diagnostic biomarkers or pathogenic agents of neuropsychiatric illness is increasingly appreciated. New technologies such as phage display immunoprecipitation sequencing (PhIP-Seq) allow for panning of human biofluids for autoantibodies against any human unmodified peptide in the human proteome. Prior work by the chief of the TIU has led to the discovery new autoantibodies and the identification of clinically relevant autoantibodies in individuals with negative clinical tests. Open-ended autoantibody discovery in diverse neuropsychiatric populations will be a core function of the TIU. Autoantibodies will be panned for research subject biofluids using PhIP-Seq, immunoprcipitation mass spectrometry, human protein array, yeast display, and other methods. It is expected that the project will lead to the identification of candidate novel autoantibodies. Validated autoantibodies can be isolated, cloned, and used as research tools to understand the pathobiological mechanism of associated neuropsychiatric symptoms. An example of this work is the TIU chief’s investigation of an anti-SARS-CoV-2 antibody that cross-reacts with a neural enzyme. The need is for a brand-name or items of peculiar to 90/90 Human ORFeome V3 (Gateway Entry Vectors) - Complete Collection The essential characteristics of the human orfeome that limit the availability to a sole source are maximal coverage of the protein coding portion of the human genome. Only this suggested source can furnish the requirements, to the exclusion of other sources, because only this suggested source has ~90% coverage of the human coding genome. The other available human orfeome collections cover about ~40% of the human coding genome, and therefore are relatively incomplete and would have limited utility. The purchase shall include the following: Human ORFeome 90/90 V3 Complete Collection • Human ORFeome 90/90 V3 Complete Collection • Human ORFeome 90/90 V3 (Gateway Entry Vectors) Complete Collection As such, no other vendor can provide the Government with the required service and maintenance renewal. This acquisition is being conducted using policies unique to the Federal Acquisition Regulation (FAR) Part 13 – Simplified Acquisition Procedures, Subpart 13.106-1(b)(1), For purchases not exceeding the simplified acquisition threshold (SAT), contracting officers may solicit from one source if the contracting officer determines that the circumstance of the contract action deem only one source reasonably available. Contracts awarded using FAR Part 13-Simplified Acquisition Procedures are exempt from the requirements of FAR Part 6-Competition Requirements. Interested parties may identify their interest and capabilities in response to this posting. The determination by the Government not to compete the proposed requirement based upon responses to this notice is solely within the discretion of the Government. Comments to this announcement, referencing this posting number, may be submitted to the CC, Office of Purchasing and Contracts, prior to the closing date specified in this announcement, electronically to the attention of Christopher Halstead, Contract Specialist, Christopher.Halstead@nih.gov by the due date and time marked in this notice.